Judge tosses defamation case brought by Ohio doctor who was acquitted of killing patients
COLUMBUS, Ohio (AP) — A former Ohio doctor who was fired before being found not guilty on murder charges in the deaths of 14 patients lost a defamation lawsuit against his former employers on Monday, after a judge stepped in for a jury on grounds the evidence presented by the defendants was incontrovertible.
Franklin County Judge Stephen McIntosh issued his directed verdict against former doctor William Husel, whose attorneys accused Michigan-based Trinity Health and Mount Carmel Health System in Columbus of orchestrating a campaign to destroy his reputation.
Husel was seeking more than $18 million from the health care companies.
His attorney, David Vermillion, said in a statement that Husel's legal team was disappointed that McIntosh would prevent the jury from making a decision in the case after weeks of evidence and testimony had been presented. He said issuing the directed verdict, a procedural move requested by the hospital, 'effectively silences the voices of those who came seeking justice.'
'This is not the outcome that any reasonable person expected, nor is it one that reflects the strength of the evidence presented," he said. 'We are evaluating all legal options, including appeal. This case has always been about more than one courtroom or one ruling. It is about truth, accountability, and the right of every individual to defend their name against false and damaging accusations.'
Mount Carmel issued a statement that said simply, 'We are pleased with the judge's decision.'
Mount Carmel Health System fired the doctor in 2018 after it concluded he had ordered excessive painkillers for about three dozen patients who died over several years.
He initially was charged with murder in 25 deaths in one of the biggest cases of its kind ever brought against a U.S. health care professional. Eleven counts were dismissed before trial.
Husel, now 49, maintained he was trying to help patients deal with their pain, sometimes in the last moments of their life, not speed up their deaths. Despite being found not guilty by a jury on murder charges in 2022, he permanently surrendered his medical license.
He filed multiple lawsuits against his former employer, accusing Trinity Health and Mount Carmel of defamation and malicious prosecution.
As part of the defamation lawsuit filed in 2019, Husel's attorneys said Trinity Health repeatedly spread lies and false information to convince the public and law enforcement that Husel was a killer, even though health system officials knew that was not true.
'Obviously, these false allegations destroyed Dr. Husel's life,' the lawsuit said. Husel gave up his medical license because his lawyers said that he knew the damage to his reputation would prevent him from working as a doctor.
In court documents filed two years ago, Husel said he had been unable to find work and was diagnosed with post-traumatic stress disorder and depression.
Trinity Health had asked a judge to toss the lawsuit, but a Franklin County judge ruled there was enough reason to move forward.
Husel, who worked in the intensive care unit, was charged in cases that involved the use of at least 500 micrograms of the powerful painkiller fentanyl. Prosecutors said ordering such dosages for nonsurgical situations indicated an intent to end lives.
His colleagues who administered the medications at Mount Carmel West Hospital in Columbus weren't criminally charged, but the hospital said it fired 23 nurses, pharmacists and managers after its internal investigation and referred various employees to their respective state boards for disciplinary action.
___
Seewer reported from Toledo.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Cirius Therapeutics Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide
MPC-inhibitor 0602K shows significant preservation of lean mass & increased muscle function combined with tirzepatide in pre-clinical DIO models 0602K shows profound beneficial transformation of adipose tissue in multiple ways & novel potential synergy with tirzepatide Both 0602K+tirzepatide and tirzepatide alone produced very similar rapid and substantial weight loss Pilot clinical study also shows 0602K by itself drives dramatic beneficial changes in muscle composition and metabolic function in patients with obesity & T2D Mitochondrial reprogramming with 0602K may add to benefits of GLP-1 weight loss with synergies in muscle & adipose tissues Data to be presented Sunday at ADA Scientific Sessions GRAND RAPIDS, Mich., June 20, 2025 /PRNewswire/ -- Cirius Therapeutics, Inc., a developer of innovative therapies for patients suffering from diseases caused by insulin resistance, including obesity/overweight and type 2 diabetes (T2D), today announced positive results from the first preclinical diet-induced obesity (DIO) studies demonstrating the potential benefits of combining 0602K and tirzepatide for patients with obesity / overweight, as well as from a pilot clinical study. Detailed data is being presented as a late-breaking poster at the American Diabetes Association's (ADA) 85th Scientific Sessions as well as a short oral presentation available online as part of the conference. "We have been advocating for the potential benefits of combining an insulin sensitizer with the latest incretin therapies, especially to more fully resolving the underlying metabolic dysfunctions in obesity, type 2 diabetes and other cardio-renal-metabolic diseases," said Dr. Ralph DeFronzo, MD, co-author and Professor of Medicine at the University of Texas Health Science Center at San Antonio. Dr. DeFronzo continued, "First generation insulin sensitizer pioglitazone has given us strong hints of the possibilities. Now, this very exciting preclinical data combining next generation insulin sensitizer 0602K with a state-of-the-art GLP-1/GIP receptor agonist, tirzepatide, further supports the enormous potential. The pilot clinical data further suggests 0602K has similar effects on body composition and metabolism in patients with obesity, and that combining the highly complementary mechanisms of 0602K and tirzepatide should drive benefits for patients beyond those already gained via weight loss." Collaborators at the Dasman Diabetes Institute in Kuwait and St. Louis University conducted parallel, independent DIO studies producing highly consistent results: Both 0602K+tirzepatide and tirzepatide alone produced very similar rapid and substantial weight loss through as long as 6 weeks treatment. 0602K + tirzepatide reduced the loss of lean mass and muscle typically seen with tirzepatide alone. Even more significantly, adding 0602K to tirzepatide increased both muscle strength and metabolic (mitochondrial) function by +50% each vs. tirzepatide alone. Adding 0602K to tirzepatide restored muscle strength/exercise capacity nearly to that of lean controls and increased mitochondrial abundance (number of mitochondria per muscle cell) by 50% over both lean controls and tirzepatide alone. 0602K + tirzepatide produced multi-faceted remodeling of adipose (fat) tissue, including reduced visceral-to-subcutaneous adipose tissue ratio (VAT:SAT), increased brown adipose tissue, and a synergistic transformation in subcutaneous adipose tissue (SAT) phenotype transformation. In SAT, 0602K and tirzepatide each produced marked decreases in adipocyte (fat cell) size, with the combination decreasing adipocyte size dramatically more than either alone. Smaller adipocytes are believed to be associated with several metabolic benefits, including an increase in numbers of "beige" adipocytes. Beige adipocytes actively consume stored fats and characteristically express uncoupling protein 1 (UCP-1), which aids in burning those fat calories. While both 0602K and tirzepatide increased UCP-1 protein in SAT by 2-3-fold over untreated high fat diet controls, the combination increased UCP1 ~7-fold with ~15% of cells UCP-1-positive. Separately, collaborators at the University of Texas Health Science Center at San Antonio conducted a small (n=3) pilot mechanistic clinical study of 0602K effects on muscle composition and metabolic function. In patients with obesity & T2D. assessed at baseline and after taking 250mg 0602K daily for 3 months: 0602K decreased intramyocellular lipid (fat inside muscle cells) by ~50% Increased muscle metabolic function (insulin-mediated glucose disposal) by ~50% Reduced HbA1c from an average of 8.33% at baseline to 6.97%. "These results support that targeting MPC with 0602K reprograms mitochondrial metabolism, not only reversing insulin resistance but also driving broad multi-organ benefits. Particularly important is 0602K synergy with GLP-1 receptor agonists we're describing here," remarked Dr. Jerry Colca, PhD, Cirius Chief Scientific Officer. Dr. Colca added, "0602K has previously been shown effective for T2D and MASH in Phase 2 clinical studies and without the side effect concerns that hung over earlier insulin sensitizers. These results highlight the need to explore the benefits of this combination particularly in patients with obesity / overweight." Cirius and several of the academic collaborators involved in the study will be available at the ADA poster (1982-LB) from 12:30-1:30 PM CDT this Sunday, June 22. Presentation Details: Title: 1982-LB - MPC-Directed Insulin Sensitizer MSDC-0602K Combines with Tirzepatide to Maintain Muscle Mass/Function and Restructure Adipose Tissue [Board No. 1982] Authors: M. Abu-Farha, J. Abubaker, F. Almulla – Dasman Diabetes Institute M. Abdul-Ghani, L. Norton, R.A. DeFronzo – University of Texas Health Sciences Center at San AntonioJ.R. Colca – Cirius TherapeuticsK.S. McCommis – St. Louis University Date & Time: Sunday, June 22, at 12:30 AM CT (poster will be up throughout meeting) Location: Poster Hall (Hall F1) About CiriusCirius is a clinical-stage pharmaceutical company focusing on mitochondrial pyruvate carrier (MPC), addressing the metabolic dysfunction that causes insulin resistance and the organ pathologies associated with type 2 diabetes (T2D) and obesity/overweight. Its lead product candidate, 0602K (azemiglitazone potassium), is a potential best-in-class novel small molecule being developed as a once-daily oral therapy designed to selectively inhibit the mitochondrial target MPC, which plays a central role in selecting mitochondrial energy substrates. MPC inhibition reprograms mitochondrial metabolism, reducing insulin resistance in cells and driving metabolic benefits in organs throughout the body. This markedly improves glycemic control in T2D, body composition in obesity, liver function and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH), and outcomes in cardiometabolic disorders. About 0602K0602K has completed 7 US clinical trials including a 52-week placebo-controlled Phase 2b study in 392 subjects with MASH with and without T2D, and a 28-day placebo-controlled Phase 2a study in 129 subjects with T2D. In those clinical studies it markedly lowered HbA1c and insulin levels, and reduced liver injury and MASH – including on top of existing GLP-1 therapy. A pilot clinical study showed 0602K markedly both reduces fat in muscle and increases muscle metabolic function in patients with obesity & T2D. Preclinical studies also demonstrate increased lean muscle mass, strength and metabolic function, together with metabolically beneficial shifts in adipose tissue phenotype ("bad fat" to "good fat"), both alone and on top of GLP-1 and GLP-1/GIP agonists. In combination with GLP-1/GIP dual agonist tirzepatide, the transformation of subcutaneous adipose tissue includes dramatic reduction in adipocyte size and synergistic increase in "beiging." Selectively targeting MPC – while avoiding PPAR-γ activation – 0602K harnesses the real-world proven efficacy of 1st generation insulin sensitizers, such as pioglitazone, but without their side effect concerns. Directly correcting a major underlying pathophysiology of chronic metabolic disease, 0602K has the potential to become a cornerstone of therapy. Coupling this potent pharmacology with that of the GLP-1s could particularly benefit patients with T2D, obesity/overweight and other cardiometabolic diseases. View original content to download multimedia: SOURCE Cirius Therapeutics
9 hours ago
Starbucks testing new protein cold foam, here's what to know
Starbucks announced a new product being developed that taps into the growing consumer obsession with protein-packed diets, this time in the form of foam. The Seattle-based coffee company first shared the news of a protein cold foam innovation earlier this month at its 2025 Leadership Experience conference. The company said it's reimagining its beverage and food offerings to build a more modern and hype-worthy global menu in an effort to resonate with customers. Starbucks introduced its new approach for testing menu items in the U.S. that -- the Starting Five process -- in which it will consider employee and customer feedback before a national launch. Starbucks tests new banana protein cold foam One such relevant health trend-informed products that's quickly drawing online attention from protein and coffee consumers that will be using this test to market model is a new banana protein cold foam. While the protein foam currently being tested contains 15 grams of protein, the company suggested that the beverages may continue to evolve.
Yahoo
9 hours ago
- Yahoo
What to know about new protein cold foam at Starbucks
Starbucks announced a new product being developed that taps into the growing consumer obsession with protein-packed diets, this time in the form of foam. The Seattle-based coffee company first shared the news of a protein cold foam innovation earlier this month at its 2025 Leadership Experience conference. The company said it's reimagining its beverage and food offerings to build a more modern and hype-worthy global menu in an effort to resonate with customers. Starbucks introduced its new approach for testing menu items in the U.S. that -- the Starting Five process -- in which it will consider employee and customer feedback before a national launch. One such relevant health trend-informed products that's quickly drawing online attention from protein and coffee consumers that will be using this test to market model is a new banana protein cold foam. While the protein foam currently being tested contains 15 grams of protein, the company suggested that the beverages may continue to evolve. At the time of publication, Starbucks confirmed to ABC News there are no additional details.
